CervoMed
CRVO
12 hedge funds and large institutions have $1M invested in CervoMed in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.67% less ownership
Funds ownership: 6.8% → 6.13% (-0.67%)
20% less funds holding
Funds holding: 15 → 12 (-3)
28% less capital invested
Capital invested by funds: $1.39M → $1M (-$383K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$11.9K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$2.88K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TI
Trexquant Investment
Stamford,
Connecticut
|
-$71K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$49K |
| 3 |
Renaissance Technologies
New York
|
-$32.2K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $389K | -$49K | -4,832 | -9% |
|
|
2
Renaissance Technologies
New York
| $235K | -$32.2K | -3,176 | -10% |
|
3
BlackRock
New York
| $176K | – | – | – |
|
4
Geode Capital Management
Boston,
Massachusetts
| $91K | – | – | – |
|
|
BCM
5
Bridgeway Capital Management
Houston,
Texas
| $89K | – | – | – |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $11K | +$11.9K | +1,169 | +717% |
|
|
7
UBS Group
Zurich,
Switzerland
| $5K | +$2.88K | +284 | +99% |
|
8
Morgan Stanley
New York
| $3K | – | – | – |
|
9
Osaic Holdings
Scottsdale,
Arizona
| $3K | – | – | – |
|
10
Wells Fargo
San Francisco,
California
| $1K | – | – | – |
|
|
TI
11
Trexquant Investment
Stamford,
Connecticut
| – | -$71K | -7,087 | Closed |
|
|
CS
12
Credit Suisse
Zurich,
Switzerland
| – | -$1K | -53 | Closed |
|
CRVO Hedge Fund Activity: Q3 2022 in Review
12 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in CervoMed (CRVO) for Q3 2022, worth a combined $1M — down 28% from $1.39M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CRVO and 0 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 2 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $11.9K. The largest seller was Trexquant Investment, exiting entirely with an estimated $71K sold.
- 12 institutional investors held CervoMed (CRVO) as of Q3 2022, down from 15 in Q2 2022.
- Funds reported $1M of CervoMed stock for Q3 2022, down 28% quarter-over-quarter.
- 0 funds opened new CervoMed positions in Q3 2022 and 3 closed out, a net change of -3 holders.
- The largest CervoMed buyer in Q3 2022 was Tower Research Capital (TRC), an estimated $11.9K added.
- The largest CervoMed seller in Q3 2022 was Trexquant Investment, an estimated $71K sold.
Based on aggregated 13F filings for Q3 2022.